GILEAD SCIENCES EUROPE LTD.
Company Information
- Company Number
- 05510315
- Registered Address
- 2 Roundwood Avenue, Stockley Park, Uxbridge, Middlesex, UB11 1AF
- Status
- Active
- Employee Count
- 536
- Turnover
- £334,972,000
- EBITDA
- £85,593,000
Additional Details
- Company Type
- Private limited Company
- Incorporated On
- 15 July 2005
- Nature of Business
- 82990 - Other business support service activities not elsewhere classified
- Industries
- Professional Services
- Region
- London
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 28 Jul 2025 | 35 | 60% | 34% | 6% | 39% |
| 01 Jul 2024 - 31 Dec 2024 | 30 Jan 2025 | 31 | 50% | 47% | 3% | 50% |
| 01 Jan 2024 - 30 Jun 2024 | 26 Jul 2024 | 32 | 71% | 24% | 5% | 34% |
| 01 Jul 2023 - 31 Dec 2023 | 30 Jan 2024 | 32 | 73% | 20% | 7% | 32% |
| 01 Jul 2022 - 31 Dec 2022 | 17 Jan 2023 | 28 | 85% | 11% | 4% | 22% |
| 01 Jul 2021 - 31 Dec 2021 | 21 Jan 2022 | 33 | 79% | 14% | 7% | 37% |
| 01 Jan 2020 - 30 Jun 2020 | 27 Jul 2020 | 31 | 68% | 24% | 8% | 30% |
| 01 Jan 2019 - 30 Jun 2019 | 22 Jul 2019 | 26 | 83% | 13% | 4% | 17% |
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | 25 | 86% | 10% | 4% | 14% |
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 | 27 | 73% | 22% | 5% | 27% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Payment made on undisputed amounts 30-45 Days after receipt of the invoice. Once an invoice is approved it is sent for payment in the next available weekly payment run.
Were there any changes to the standard payment terms in the reporting period?
Payment terms were changed in H1 2025 to be 45 days as standard for new suppliers with existing suppliers remaining on existing terms (mostly 30 days).
Any other information about payment terms
Gilead reserves the right to withhold payment of any invoice or part of an invoice to the extent that the services/goods provided are not in accordance with the agreement entered into. We also reserve the right to set off any liability of supplier to Gilead against any liability of Gilead to supplier.
Maximum contractual payment period agreed
45
Dispute Resolution Process
Each engagement with a supplier will be managed by a Gilead business owner. Should a dispute arise in relation to payment for such engagement, it will be discussed by the supplier and the relevant Gilead business owner as soon as possible and escalated internally with a view to reaching resolution.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
Gilead Sciences Europe Ltd. is a biopharmaceutical company that focuses on developing innovative treatments for life-threatening diseases. They operate in over 35 countries across Europe, Middle East, and Africa.
Sustainability is a key focus for Gilead Sciences Europe Ltd. They are committed to reducing their environmental impact and promoting sustainable practices throughout their operations. They have implemented various initiatives such as reducing carbon emissions, promoting energy efficiency, and reducing waste.
The company's products and services include treatments for HIV, viral hepatitis, and other serious medical conditions. They have a wide portfolio of medicines that are approved for use in Europe, and they continue to invest in research and development to bring new treatments to patients.
The key people at Gilead Sciences Europe Ltd. include their President, Christina M. Trinchieri, and their Executive Vice President and Chief Financial Officer, Andrew Dickinson. They are supported by a team of experienced leaders in the biopharmaceutical industry.
Customers and stakeholders can contact Gilead Sciences Europe Ltd. through their website, which provides detailed information about their products, clinical trials, and corporate responsibility efforts. Their registered office address is located in Cambridge, United Kingdom.
In conclusion, Gilead Sciences Europe Ltd. is a leading biopharmaceutical company with a strong focus on sustainability and developing life-saving treatments. Their commitment to innovation and responsible business practices make them a trusted partner in the healthcare industry.
